A new clinical study reports that 20µg of LSD significantly reduces pain perception. This promising investigation builds on the little-known history of research into LSD as a potential analgesic.
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
Researchers will examine whether MDMA can offset some of the negative side effects of LSD in a therapeutic setting.
Two studies indicate that higher doses of psilocybin are necessary for sustained reductions in depression and anxiety.
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Three clinical trials are underway to find out if these psychedelic compounds can provide relief for patients.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
“In the pharmaceutical drug development community, this is what you dream about.”
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
Eleusis’s Phase I Alzheimer’s Trial Finds Favorable Safety & Tolerability of LSD in Older Volunteers
There were no abnormalities or deviations in safety or cognitive outcome measures compared to the baseline data.